راضیه رضوی پاریزی

Breast cancer is one of the most common malignancies among women, and the search for novel therapeutic agents with anticancer potential remains a priority. Many nanotechnology products have been recognized as promising candidates in cancer diagnosis, prevention, and treatment due to their small size, large surface area, and high reactivity. Magnetic iron oxide nanoparticles (IONPs) have attracted extensive interest due to their magnetic physicochemical properties in the biomedical and industrial fields. In this study, green-synthesized iron oxide nanoparticles were used. MCF-7 cells were grown in DMEM media supplemented with 10% fetal bovine serum in 96-well plates to 80% confluence. Fe3O4 NPs were solubilized in 100% DMSO and then diluted in serum-free medium to reach a concentration of 0.5% DMSO. Cells were washed and exposed to Fe3O4 NPs at concentrations of 10, 25, 50, 75, and 100 μg/ml for 24 hours. At the end of the incubation period, the MTT assay was used to determine the cell viability. The absorbance was read at 570 nm by a microplate reader. According to the results, green-synthesized IONps demonstrated IC50 values greater than 100 μg/ml, and no significant reduction in cell viability was observed compared to the control. Very high doses were required to achieve a cytotoxic effect, which can be considered a limiting factor from a clinical perspective. In conclusion, this study reports that green-synthesized iron oxide nanoparticles do not exhibit anticancer activity against MCF-7 cells, and achieving therapeutic efficacy may require longer exposure times or combination with other therapeutic agents.